Role of Sarcopenia in Nonalcoholic Fatty Liver Disease: Definition Is Crucially Important

Peng, Tao‐Chun

doi:10.1002/hep.29910

Cited by 6 publications

(3 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this situation, fatty acids released from skeletal muscle might aggravate insulin resistance and liver steatosis in MAFLD patients ( 30 , 31 ). Secondly, liver steatosis and ASMI both were affected by BMI (a parameter calculated by height and weight) ( 32 , 33 ), in our study, most individuals with large ASMI also showed higher height and weight, and the corresponding liver steatosis was more serious. Thirdly, MAFLD was associated with a variety of metabolic abnormalities, which might affect the relationship between ASMI and steatosis.…”

Section: Discussionmentioning

confidence: 50%

Appendicular Skeletal Muscle Index and HbA1c Evaluate Liver Steatosis in Patients With Metabolic Associated Fatty Liver Disease

Jin

Wang

et al. 2022

Front. Med.

View full text Add to dashboard Cite

Background and Aim(s)Liver steatosis, as the main feature of metabolic associated fatty liver disease (MAFLD), was associated with the progression of liver fibrosis and metabolic syndrome, which needed to be estimated accurately. In this study, we explored the significance of appendicular skeletal muscle index (ASMI) in evaluating liver steatosis of MAFLD patients.MethodsEight hundred and ninety-nine cases with MAFLD from 2017 to 2018 National Health and Nutrition Examination Surveys (NHANES) database were included. All the analyzed data were obtained from NHANES database. The association between ASMI and liver steatosis were evaluated using R and EmpowerStats.ResultsMAFLD individuals were randomly divided into a training (n = 450) and validation cohort (n = 449). In univariate analysis, HbA1c, arms fat, arms lean mass, legs lean mass, trunk lean mass, total fat, total lean mass and ASMI were significantly associated with liver steatosis (p < 0.05). Multivariate analysis showed that HbA1c (OR: 1.6732; 95% CI: 1.2753–2.1929, p = 0.0002) and ASMI (OR: 1.6723; 95% CI: 1.1760–2.5204, p = 0.0052) were independently associated with severe liver steatosis. ASMI accurately evaluated severe liver steatosis with an AUROC of 0.73 and 0.81 in training and validation cohort, respectively. Compared with ASMI only, ASMI combined with HbA1c improved the AUROC to 0.85 and 0.88. Furthermore, the AUROC of our model was superior to FLI in the evaluation of liver steatosis.ConclusionASMI combined with HbA1c has good evaluation value for liver steatosis in MAFLD patients, which might be beneficial for the management of MAFLD clinically.

show abstract

Section: Discussionmentioning

confidence: 50%

Appendicular Skeletal Muscle Index and HbA1c Evaluate Liver Steatosis in Patients With Metabolic Associated Fatty Liver Disease

Jin

Wang

et al. 2022

Front. Med.

View full text Add to dashboard Cite

show abstract

“…Where muscle dysfunction attributed to low muscle volume occurs in the face of obesity, the combination is referred to as sarcopenic obesity [ 38 , 39 ]; age-related muscle deterioration accompanied by increases in body fat mass has been identified [ 40 ]. Peng et al [ 35 , 41 ] noted that BMI confounds the relationship between sarcopenia and NAFLD in studies using different definitions for sarcopenia. We also know that BMI is limited as an estimate of body fatness, and it varies with age, sex, and ethnicity [ 42 , 43 ].…”

Section: Discussionmentioning

confidence: 99%

Fatty Liver Index and Skeletal Muscle Density

et al. 2022

View full text Add to dashboard Cite

Accumulation of fat in the liver and skeletal muscle is associated with obesity and poor health outcomes. Liver steatosis is a characteristic of non-alcoholic fatty liver disease (NAFLD) and myosteatosis, of poor muscle quality in sarcopenia. In this study of 403 men (33–96 years), we investigated associations between the fatty liver index (FLI) and muscle density, as markers of fat accumulation in these organs. We also investigated associations between the FLI and parameters of sarcopenia, including DXA-derived appendicular lean mass (ALM) and handgrip strength by dynamometry. Muscle density was measured using pQCT at the radius and tibia. FLI was calculated from BMI, waist circumference, and levels of triglycerides and gamma-glutamyltransferase. There was a pattern of decreasing muscle density across increasing quartiles of FLI. After adjusting for age and lifestyle, mean radial muscle density in Q4 was 2.1% lower than Q1 (p < 0.001) and mean tibial muscle density was 1.8% lower in Q3 and 3.0% lower in Q4, compared to Q1 (p = 0.022 and < 0.001, respectively). After adjusting for age and sedentary lifestyle, participants in the highest FLI quartile were sixfold more likely to have sarcopenia. In conclusion, our results suggest that fat accumulation in the liver co-exists with fat infiltration into skeletal muscle.

show abstract

“…There are studies that indicate that when sarcopenia is correlated with NAFLD when the BMI is higher and correlates NAFLD with sarcopenic obesity [48]. The patients with lower muscle mass have a higher risk of developing NAFLD (OR = 3.42, 95% CI 1.30-8.96, p = 0.002) [49].…”

Section: Assessment Of Sarcopeniamentioning

confidence: 99%

Diagnostic Criteria and Prognostic Relevance of Sarcopenia in Patients with Inflammatory Bowel Disease—A Systematic Review

Potcovaru

Filip

Neagu

et al. 2023

JCM

View full text Add to dashboard Cite

Background: Sarcopenia is a syndrome characteristic in elderly patients and is also associated with a significant proportion of chronic disorders such as inflammatory bowel disease (IBD). In this case, it can lead to a worse prognosis of the disease and a decreased quality of life. Study Aim: This study aims to identify the best ways to diagnose sarcopenia in patients with IBD, establish its impact on the course of the disease, and find preventive methods to counteract the effects of sarcopenia in the outcome of patients with IBD and, therefore, minimize disabilities and increase the health-related quality of life (HRQoL). Material and Methods: A systematic review with the Prospero registration number CRD42023398886 was performed in PubMed and Web of Science databases, evaluating all original articles published in the last 10 years (clinical trials and randomized control trials) that describe sarcopenia and IBD in the human adult population. Results: From the 16 articles that were included, 5 articles defined sarcopenia by the skeletal muscle index (SMI) and reported data regarding its correlation with body composition: BMI; visceral fat (VF); subcutaneous fat (SC); and VF/SC index. Other articles evaluated the link between sarcopenia and the total psoas muscle area, thigh circumference, calf circumference, subjective global assessment, hand grip strength, and appendicular SMI, alongside inflammatory markers such as IL-6 and C-reactive protein, level of disability, malnutrition, frailty, resistance training alone and in combination with whey protein, and infliximab treatment. Discussions and Conclusions: There is a great heterogeneity regarding the assessment criteria and methods used to diagnose sarcopenia due to the variability of population characteristics, both anthropometric and socio-cultural, alongside the high variability in the cut-offs. Therefore, any method which identifies sarcopenia in IBD patients, thus enabling intervention, may provide good results for patient quality of life and outcomes.

show abstract

Role of Sarcopenia in Nonalcoholic Fatty Liver Disease: Definition Is Crucially Important

Cited by 6 publications

References 5 publications

Appendicular Skeletal Muscle Index and HbA1c Evaluate Liver Steatosis in Patients With Metabolic Associated Fatty Liver Disease

Appendicular Skeletal Muscle Index and HbA1c Evaluate Liver Steatosis in Patients With Metabolic Associated Fatty Liver Disease

Fatty Liver Index and Skeletal Muscle Density

Diagnostic Criteria and Prognostic Relevance of Sarcopenia in Patients with Inflammatory Bowel Disease—A Systematic Review

Contact Info

Product

Resources

About